Back to News
Market Impact: 0.2
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
Source: PR Newswire
Healthcare & Biotech
Wenda Pharma said it will publish phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma at the 2026 ESMO Annual Meeting. The article excerpt provides no trial results or numerical efficacy or safety data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- ArriVent reports phase 1 data for cancer drug ARR-217
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- UK immigration crackdown threatens £15 billion care sector
- US Midterm Elections 2026: Key Issues, From Affordability to AI
- Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product